First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer – Final survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110)
-
Published:2022-09
Issue:
Volume:173
Page:194-203
-
ISSN:0959-8049
-
Container-title:European Journal of Cancer
-
language:en
-
Short-container-title:European Journal of Cancer
Author:
Stahler ArndtORCID,
Modest Dominik P.,
Fischer von Weikersthal LudwigORCID,
Kaiser Florian,
Decker Thomas,
Held Swantje,
Graeven Ullrich,
Schwaner IngoORCID,
Denzlinger Claudio,
Schenk Michael,
Kurreck AnnikaORCID,
Heinrich Kathrin,
Gießen-Jung Clemens,
Neumann JensORCID,
Kirchner Thomas,
Jung Andreas,
Stintzing SebastianORCID,
Heinemann Volker
Subject
Cancer Research,Oncology
Reference25 articles.
1. Treatment of patients with late-stage colorectal cancer: ASCO resource-stratified guideline;Chiorean;JCO Glob Oncol,2020
2. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer;Van Cutsem;Ann Oncol,2016
3. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer – a GERCOR study;Tournigand;J Clin Oncol,2006
4. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial;Hegewisch-Becker;Lancet Oncol,2015
5. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer;Hurwitz;N Engl J Med,2004
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献